Open a bathroom cabinet almost anywhere in the world and you are looking at Kenvue's product line. The Tylenol next to the sink, the Neutrogena in the shower, the Listerine on the shelf, the Band-Aid in the drawer, the Aveeno lotion, the Zyrtec for allergy season - one company makes all of them. Almost nobody can name it. That gap, between brands everyone knows and a corporate name almost no one does, is the whole story of Kenvue.
Kenvue Inc. was carved out of Johnson & Johnson and became an independent public company in May 2023. In a single step it inherited more than a century of consumer brands and turned into the world's largest pure-play consumer health company by revenue - roughly $15 billion in annual sales, products in more than 165 countries, and about 22,000 employees the company calls "Kenvuers."
What Kenvue doesThree shelves, one company
Kenvue is a branded consumer packaged goods business built around everyday health. It develops, manufactures and sells over-the-counter medicines, skin care and personal care products - the kind of things people buy on repeat without thinking much about who makes them. Internally, the portfolio is sorted into three segments, and the split is really a map of the moments people reach for a product.
Segments shown for structure, not exact reported revenue weighting.
Self Care is the medicine drawer: Tylenol and Motrin for pain and fever, Zyrtec and Benadryl for allergies, Sudafed for congestion, Nicorette and Nicoderm CQ for quitting smoking, Pepcid and Imodium for digestion. Skin Health & Beauty is dermatologist territory - Neutrogena, Aveeno, Clean & Clear and OGX. Essential Health is the everyday staples: Band-Aid, Listerine, Johnson's baby products, Desitin and Bengay.
Kenvue's purpose is to realize the extraordinary power of everyday care.— Kenvue, corporate mission
Who buys itEveryone, on repeat
The customer base is about as broad as a company can have: ordinary households in nearly every market on earth. Kenvue reaches them through mass retailers, drugstores and pharmacies, and - increasingly - through e-commerce. On its early earnings calls the company flagged Amazon as a growing destination for the self-care category, a shift that has reshaped how over-the-counter products get discovered and bought.
There is a second, quieter customer too: the healthcare professional. Doctors, dermatologists and pharmacists sit behind much of Kenvue's brand equity. "Dermatologist recommended" is not a tagline for Neutrogena so much as a business model - trust handed down from a professional to a shopper standing in an aisle.
The problem it solvesCare you don't have to think about
Kenvue's products handle the small, constant maintenance of being a person: a headache at 2am, a scraped knee, a sunburn to prevent, a cold to get through, a habit to quit. None of it is dramatic. All of it is relentless. The value Kenvue offers is a default answer to those moments - a trusted, science-backed product you can reach for without research, in a category where getting it wrong feels risky and getting it right feels invisible.
How it's differentPure-play, at scale
Plenty of giants sell consumer health as one line among many - Procter & Gamble, Unilever, Colgate-Palmolive, Reckitt, L'Oreal and Beiersdorf all compete for shelf space. Kenvue's closest structural parallel is Haleon, the consumer health business GSK spun off. What sets Kenvue apart is focus and depth: it is a pure-play consumer health company, the largest by revenue, carrying a roster of brands that have led their categories for decades. Where a diversified conglomerate spreads attention across food, home care and cosmetics, Kenvue points all of it at self-care, skin health and essential health.
Everyday care is for everyone, everywhere.— Kenvue
Business model & moneyTrust, sold by the unit
The model is classic CPG: high-frequency, largely non-discretionary purchases, sold through many channels at scale, with pricing power resting on brand equity and professional endorsement rather than novelty. Kenvue's 2023 debut was itself a landmark - its initial public offering raised roughly $4.37 billion, the largest US IPO of the year, and the company started life valued at about $41 billion.
ExpertiseNew name, 130-year memory
Kenvue is simultaneously a start-up and an institution. The company was named and incorporated in 2022 and only became independent in 2023 - yet the brands it manages trace back to Johnson & Johnson's 1886 founding. That inheritance shows up as deep capability in the unglamorous disciplines that make consumer health work: regulatory affairs, product safety and efficacy testing, clinical studies, formulation science, and the machinery of managing a global brand portfolio across 165-plus regulatory regimes.
The name itself nods to that mix. "Ken" is an old word for knowledge; "vue" evokes sight - knowledge you can see, which is roughly what a trusted health brand is meant to be.
Where it fitsThe seam between pharma and CPG
Kenvue lives at an unusual intersection: more consumer than a drugmaker, more clinical than a snack company. It is a consumer packaged goods business whose products are held to healthcare standards, sold with the marketing muscle of retail. That position is exactly what made it attractive - and, in 2025, contested.
A turbulent 2025Activists, a claim, and a buyer
For a two-year-old company, 2025 was eventful. Activist investors - Starboard Value, Third Point and Toms Capital among them - pressed for faster growth and fatter margins, with Starboard taking a board seat. In July, Kenvue removed chief executive Thibaut Mongon, who had led the company since the spin-off, and named board member Kirk Perry - a 23-year Procter & Gamble veteran and former Circana CEO - as interim chief while a strategic review advanced.
Then came a reputational shock. In September 2025 the Trump administration publicly linked acetaminophen - Tylenol's active ingredient - to autism when used in pregnancy, an assertion that is not established by scientific evidence. The claim moved Kenvue's stock and revived litigation the company had largely fended off; in October, Texas sued Kenvue and Johnson & Johnson over Tylenol marketing. It was a stark lesson in what happens when a company's core asset is trust: the attack surface is trust too.
The review ended with a sale. On November 3, 2025, Kimberly-Clark - the maker of Kleenex and Huggies - agreed to acquire Kenvue in a cash-and-stock deal valued at roughly $48.7 billion, one of the largest consumer deals in years. Shareholders overwhelmingly approved it in January 2026, with closing targeted for the second half of 2026.
The short, loud life of KVUEFrom carve-out to acquisition
- 2021J&J announces the splitJohnson & Johnson reveals plans to separate its consumer health business from pharma and medtech.
- 2022Kenvue is named and incorporatedThe future company gets its name and is set up as a separate entity.
- 2023IPO and independenceKenvue lists on the NYSE as "KVUE" in May - the largest US IPO of the year.
- 2024First full year aloneReports roughly $15 billion in sales across its three segments.
- 2025A year of upheavalCEO change, activist pressure, the Tylenol autism controversy, and a $48.7B deal with Kimberly-Clark.
- 2026Shareholders approve the saleInvestors vote in favor of the acquisition; closing targeted for the second half of the year.
However the Kimberly-Clark deal ultimately closes, the underlying business is the same one that started this story: the quiet supplier to the world's bathroom cabinets. Kenvue built a company on being the answer people reach for without thinking. In 2025, the harder question was whether it could take some of its own everyday care.